Background: Inflow occlusion on beating heart and cardiopulmonary bypass techniques have been proposed for the removal of foreign material, such as stents, catheters and mass lesions, from cardiac chambers. However, both techniques are not devoid of disadvantages and complications. In this article, we define an alternative, novel 'double-hole' technique, which is based on opening the right atrium without cardiopulmonary bypass. Methods: Bovine hearts were obtained from a local supermarket. Two purse-string sutures were placed in the right atrium using 2-0 braided, non-absorbable polyester suture material, one close to the auricle, and the other close to the interatrial septum. The guidewire of a haemodialysis catheter was inserted through the superior vena cava into the right atrium and passed all the way through the right ventricle. Results: We suggest that the double-hole technique may be useful, especially in revision cases with adhesions. Further research should be performed to document the efficacy and safety of this method.
Inflow occlusion on a beating heart (IOBH) is a technique that was used more often in cardiovascular surgery before the cardiopulmonary bypass (CPB) era. Nowadays, this technique is reserved for cases such as pulmonary or aortic valvotomy, cardiac injury, atrial septectomy and extraction of intracardiac thrombus or foreign body. [1] [2] [3] CPB can alternatively be used for these operations. Complications may arise due to technical issues, such as tissue injury during cannulation or embolic events. Peri-operative problems arising from the inflammatory process caused by extracorporeal circulation signify that CPB is not a technique devoid of complications, in comparison to IOBH. 1 To eliminate the disadvantages of IOBH and CPB, we have developed a novel technique on a bovine heart. We hope that the 'double-hole' technique could provide a safe and effective alternative in the removal of foreign material such as catheters and pacemaker leads.
methods
All animal studies were carried out with the approval of the Institutional Animal Care and Use Committee. Bovine hearts were obtained from a local supermarket. Two purse-string sutures were placed in the right atrium using 2-0 braided, non-absorbable polyester suture material (Ticron ® , Covidien, Norwalk, CT 06856, USA), one close to the auricle, and the other close to the interatrial septum.
The guidewire of a haemodialysis catheter was inserted through the superior vena cava into the right atrium and passed all the way through the right ventricle. A stab wound was made within the purse-string sutures and the left index finger was introduced into the right atrium through the dilated hole, close to the auricle. In the right hand, a curved haemostatic clamp was introduced through the dilated hole, close to the interatrial septum (Fig. 1A) . A guidewire or catheter inside the right atrium was pushed towards the other hole with the tip of the left index finger and caught with the clamp in the other hole, held by the right hand, and extracted (Fig. 1B) .
Following visualisation and extraction, the wire was cut into proximal and distal pieces. The proximal piece was extracted ( Fig. 2A) , and the distal piece was then removed (Fig. 2B) . Repetition of this procedure revealed that we were able to retrieve the wire with the clamp every time, and the two pieces of wire were removed, where after the right atrium was closed with snares. IOBH is a well-known but uncommonly used technique to remove mass lesions and foreign material such as pacemaker leads and catheters from the right atrium. 1 In this technique, blood flow from the superior and inferior vena cavae to the right atrium is prevented by occlusion with snares, and the right atrium is then opened. This method has significant disadvantages, such as bleeding, hypotension, air embolism, difficulty of surgical exposure, and the necessity to be performed in a short time. Cardiac and neurological complications may occur due to systemic and cerebral malperfusion, particularly in occlusions of more than three minutes. 2 CPB may be required, particularly in cases with complicated right atrial material. This necessity arises owing to co-morbidities of the patient, extension of the material, and the potential for pulmonary embolism. Studies have demonstrated that the use of CPB is particularly common in cases with co-existence of extracardiac tumours and large, invasive right atrial thrombus. [4] [5] [6] Both IOBH and CPB techniques may be used in the extraction of intracardiac pacemaker leads, 6 and in tracheal stent implantation. 7 CPB can alternatively be used for these interventions, but widespread inflammatory response, length of operation and intubation times, and duration of intensive care unit and hospital stays are limitations of the technique. 3 These limitations become even more apparent in cases with co-morbidities. 1 To overcome these disadvantages, we have developed a novel double-hole technique for the removal of foreign material (e.g. catheters, pacemaker leads) in a bovine heart model.
In the IOBH technique, the superior and inferior vena cavae should be free from the surrounding tissue. A polyester tape is placed around each vena cava to provide occlusion of inflow. Complications such as bleeding and air embolisation may be minimised in the double-hole technique since it involves less traumatic and more haemostatic steps such as a pursestring suture, a smaller hole for clamp insertion, and gentler manipulation with the finger. The technique we describe is easy and practical to perform. While the wire is manipulated with the left index finger, it can easily be grasped repeatedly with the clamp in the right hand. Results of our preliminary report indicate that the double-hole technique could be a safe and effective option for the extraction of pacemaker leads and catheters from the right atrium. We suggest that this technique may be especially useful in revision cases with adhesions. Further research should be performed to document the efficacy and safety of this method.
The main limitation of this experimental study is that the right atria of the bovine heart are much smaller than those of a human heart. Larger atriae may cause more difficulty during surgery. Secondly, the usefulness of this procedure may in fact be limited to wires that are partly trapped in the right atrium, and hence this would include pacer wires and 'errant' guidewires. It may not be appropriate for guidewires having left the right atrium and travelled to the right ventricle or pulmonary artery.
Conclusion
We believe the double-hole technique has the potential to become a safe, practical and effective measure in the future. Further extensive research is necessary to investigate the utility of this novel technique in contemporary cardiovascular surgery. We plan to assess this technique in an in vivo model to corroborate its potential as a less-invasive extraction procedure in future research.
Cardiovascular disease market set to grow very slowly to $146.4 billion by 2022, says GBi research
The cardiovascular disease market, which includes hypertension, dyslipidaemia and thrombotic events, is set to grow from $129.2 billion in 2015 to $146.4 billion by 2022, at a very modest compound annual growth rate of 1.8%, according to business intelligence provider GBI Research.
The company's latest report states that this relative stagnation can be attributed to major product approvals coinciding with key patent expirations. Within cardiovascular disease there are a number of blockbuster products that have recently gone off-patent, and others are expected to in the coming years, many of which belong to significant players.
For example, the current market leader, AstraZeneca's Crestor (rosuvastatin), generated around $7 billion in 2011, with revenues expected to drop sharply following the expiration of its patent on 8 July 2016. Total annual revenues are forecast to be around $1.3 billion in 2022.
Thomas Jarratt, associate analyst for GBI Research, explains: 'Unlike AstraZeneca, some key players will experience revenue growth resulting from the introduction of new products to market. In particular, Sanofi's Praluent (alirocumab) is expected to help mitigate losses associated with falling revenues of its key products Lovenox (enoxaparin) and Plavix (clopidogrel).
'Novartis' heart-failure drug Entresto was introduced to market in July 2015, and GBI Research expects its revenues to increase dramatically during the forecast period. Entresto is a combination drug, which has shown efficacy in clinical trials. Coupled with a high cost, which amounts to over $4 500 annually per patient, the drug contributes to a very high revenue forecast of $5.7 billion by 2022. ' The sheer number of expirations and approvals means the structure of the market will shift significantly. Current market leader AstraZeneca is set to mitigate the damage associated with the introduction of generic Crestor through the rising revenues attributed to its antiplatelet drug Brilinta.
Jarratt continues: 'the market shares of Sanofi and Novartis are expected to increase strongly over the forecast period, leading to Sanofi becoming market leader, and both brands achieving revenues in excess of $7 billion by 2022.' 
